KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to 0.21%.

  • Halozyme Therapeutics' Return on Capital Employed fell 700.0% to 0.21% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.21%, marking a year-over-year decrease of 700.0%. This contributed to the annual value of 0.22% for FY2025, which is 900.0% down from last year.
  • Latest data reveals that Halozyme Therapeutics reported Return on Capital Employed of 0.21% as of Q4 2025, which was down 700.0% from 0.57% recorded in Q3 2025.
  • Halozyme Therapeutics' Return on Capital Employed's 5-year high stood at 0.57% during Q3 2025, with a 5-year trough of 0.15% in Q3 2022.
  • Its 5-year average for Return on Capital Employed is 0.25%, with a median of 0.24% in 2024.
  • Data for Halozyme Therapeutics' Return on Capital Employed shows a peak YoY increase of 4500bps (in 2021) and a maximum YoY decrease of -8400bps (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Return on Capital Employed stood at 0.27% in 2021, then tumbled by -42bps to 0.16% in 2022, then grew by 28bps to 0.2% in 2023, then surged by 42bps to 0.28% in 2024, then fell by -24bps to 0.21% in 2025.
  • Its Return on Capital Employed stands at 0.21% for Q4 2025, versus 0.57% for Q3 2025 and 0.34% for Q2 2025.